Market Analysis & Reporting
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
Market Analysis & Reporting
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
Market Analysis & Reporting
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
11.00
-0.02 (-0.18%)
Latest market quote · 2026-08-07 20:00 (UTC)
Company profile
Healthcare
Biotechnology
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
Company websiteIssued common shares
Shares available to trade
Sensitivity relative to the market
Reported full-time workforce
Shares held by institutions
Shares held by company insiders
Current session activity
High-to-low move
Share of advancing days
Based on daily returns
Versus provisional U.S. equity benchmark
Annualized negative-return risk
Historical one-day loss threshold
Reader research
Join the discussion
Log in to share sentiment, a price target, and your investment thesis.
Log in to commentLargest one-day advance
Largest one-day decline
Largest one-year decline
Low-to-high range position
Shares sold short
Percent of public float
Short-interest ratio
Nearest-expiry open interest
Price, momentum, breadth and range
Scores are technical indicators derived from the available one-year price history and are not investment recommendations. Short-interest and options figures display when supplied by the market-data provider.